Skip to content
HowShorted

INTERCEPT PHARMACEUTICALS, INC. short interest in 2023

In 2023, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 8.51% of shares outstanding on 13 Jan 2023 to 24.26% on 31 Oct 2023, a change of +15.75 percentage points. The year's high was 29.53% on 15 Sep 2023 and its low 6.17% on 15 Feb 2023, averaging 15.24% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.90 days on 31 Aug 2023. Full history: INTERCEPT PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023

Aggregate net short position time series for INTERCEPT PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
8.51% (13 Jan 2023)
End of year
24.26% (31 Oct 2023)
Change
+15.75 pp
High
29.53% (15 Sep 2023)
Low
6.17% (15 Feb 2023)
Average
15.24%
Highest days to cover
15.90 (31 Aug 2023)
SEC filings marked
7

Every report in 2023

INTERCEPT PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20238.51%3.91
31 Jan 20237.60%5.00
15 Feb 20236.17%3.21
28 Feb 20237.84%4.68
15 Mar 20238.02%3.8410-K filed, results (8-K)
31 Mar 20239.32%5.53
14 Apr 20239.15%4.32
28 Apr 20238.86%4.3510-Q filed, results (8-K)
15 May 20237.68%5.14
31 May 202312.40%1.83
15 Jun 202315.32%5.58
30 Jun 202317.21%3.94
14 Jul 202317.90%7.45
31 Jul 202320.42%13.21
15 Aug 202322.78%11.8610-Q filed, results (8-K)
31 Aug 202324.89%15.90
15 Sep 202329.53%10.23
29 Sep 202322.57%1.61
13 Oct 202324.39%4.01
31 Oct 202324.26%8.34

See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.